ArticleEndocrine connections2026
Neural plasticity impairment in chronic post-surgical hypoparathyroidism: a cross-sectional and prospective pilot study.
Article in Endocrine connections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pharmacodynamics of sustained levels of PTH following palopegteriparatide treatment in adults with hypoparathyroidism.Journal of the Endocrine Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite adequate conventional therapy, patients with chronic post-surgical hypoparathyroidism (HypoPT) frequently report persistent physical, emotional, and cognitive symptoms that affect quality of life, despite no overt cognitive impairment. The neurophysiological mechanisms underlying these complaints remain unclear. Purpose: To assess cortical excitability and plasticity in HypoPT patients using transcranial magnetic stimulation (TMS) and to explore the effects of parathyroid hormone (PTH) therapy on these parameters. Methods: We conducted a cross-sectional study including 32 HypoPT patients on stable conventional treatment without significant cognitive impairment and 16 age-matched healthy controls. In a prospective observational phase, a subgroup of six HypoPT patients (3-palopegteriparatide and 3-teriparatide) was reassessed after 48 months of PTH therapy. All participants underwent TMS evaluation, including motor evoked potentials (MEPs), short-latency afferent inhibition (SAI), short-interval intracortical inhibition (SICI), and assessment of plasticity using intermittent theta burst stimulation (iTBS). The primary outcome was the change in MEP amplitude after iTBS as an index of cortical plasticity. Results: MEP changes following iTBS differed significantly between HypoPT patients and controls (-0.02 vs 0.4 mV; P = 0.003; corrected P = 0.042), indicating reduced cortical plasticity in HypoPT. In contrast, HypoPT patients receiving long-term PTH therapy showed a significant increase in MEP amplitude, comparable to healthy controls. No other TMS measures differed significantly. Conclusion: This pilot study provides preliminary evidence of impaired cortical plasticity in HypoPT in the absence of overt cognitive impairment. Although limited by small sample size, the findings suggest that PTH therapy may modulate cortical plasticity. Further research is needed to clarify the clinical relevance and potential central nervous system effects of PTH in HypoPT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.